Merck & Co. - רווח למניה ב-12 החודשים האחרונים MRK

The prospects for Merck & Co., Inc. (MRK) depend on new developments in cardiology and oncology due to the upcoming patent expiration of Keytruda. The current EPS YoY TTM growth rate confirms the resilience of this trend, with the value stabilizing at -87.20. Gardasil vaccine sales and dividend payments provide stability. The monopoly status of the flagship drug guarantees premium pricing power despite regulatory pressure in the US.

Amidst a fierce battle for oncology leadership and the risks of patent expiration, Merck & Co., Inc. (MRK) is compelled to constantly scale its profits. This metric measures the percentage change in net earnings per share over a rolling year, reflecting the efficiency of R&D expenditures. This allows investors to distinguish organic growth from temporary market fluctuations. By analyzing the annual EPS growth rate over the last 12 months, one can assess the sustainability of the company's capitalization.